Estimation of the correlation serum resistin with metabolic syndrome
Paper Details
Estimation of the correlation serum resistin with metabolic syndrome
Abstract
Adipose tissue-derived adipokines play important role in metabolic syndrome and obesity related disease. Although the molecular mechanisms for this are less understood. In this study, we determined serum resistin in relation to metabolic syndrome determinants. For this purpose, Fasting blood samples were collected from brachial vein in 39 sedentary adult overweight – obese men aged 35 – 43 years in body mass index (BMI) ranged 28 to 33 kg/m2 in order to measuring serum resistin, lipid profile and glucose concentration. Anthropometrical indexes and blood pressure were also measured in all participants. Pearson rank correlation analysis were used for determine relationship between resistin with metabolic syndrome determinants. A p-value less than 0.05 were considered statistically significant. Serum resistin levels correlated positively with BMI, body fat percentage (BF%), Total cholesterol (TC), low density lipoprotein (LDL), age, visceral fat, waist to hip ratio (WHO), systolic and diastolic blood pressure in studied subjects. A borderline signigcant positive association was observed between serum resistin and glucose concentration. Resistin as an inflammation cytokine is associated with metabolic syndrome in obese subjects.
Antuna-Puente B, Feve B, Fellahi S, Bastard JP. 2008. Adipokines: The missing link between insulin resistance and obesity. Diabetes Metab 34(1), 2-11.
Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, et al. 2004. Regulation of fasted blood glucose by resistin. Science 303, 1195-8.
Ford ES, Giles WH, Dietz WH. 2002. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey”. JAMA 287 (3), 356–359.
Fukui Y, Motojima K. 2002. Expression of resistin in the adipose tissue is modulated by various factors including peroxisome proliferator-activated receptor α. Diabetes Obes. Metab. 4, 342–345.
Holcomb IN, Kabakoff RC, Chan B. 2000. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. Embo J. 19, 4046-4055.
Kershaw E, Flier J. 2004. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab 89 (6), 2548–2556.
Le Lay S, Boucher J, Rey A. 2001. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem. Biophys. Res. Commun. 289, 564-567.
Lee JH, Bullen Jr JW, Stoyneva VL, Mantzoros CS. 2005. Circulating resistin in lean, obese and insulin-resistant mouse models: lack of association with insulinemia and glycemia. Am. J. Physiol. Endocrinol. Metab 288, 625–632.
Maebuchi M, Machidori M, Urade R, Ogawa T, Moriyama T. 2003. Low resistin levels in adipose tissues and serum in high-fat fed mice and genetically obese mice :development of an ELISA system for quantification of resistin. Arch. Biochem. Biophys 416, 164–170.
Makimura H, Mizuno TM, Bergen H, Mobbs CV. 2002. Adiponectin is stimulated by drenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am. J. Physiol. Endocrinol. Metab. 283, 1266–1271.
McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. 2002. Resistin, central obesity, and type 2 diabetes. Lancet 359, 46–47.
Meier U, Gressner AM. 2004. Endocrine Regulation of Energy Metabolism: Review of Pathobiochemical and Clinical Chemical Aspects of Leptin, Ghrelin, Adiponectin, and Resistin. Clin Chem 50(9), 1511-25.
Mojiminiyi OA, Abdella NA. 2007. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 67(2), 215-25.
Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. 2007. Plasma resistin levels correlate with determinants of the metabolic syndrome Eur J Endocrinol 156(2), 279-84.
Rajala MW, Lin Y, Ranalletta M. 2002. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-α in adipose tissue. Mol. Endocrinol. 16, 1920–1930.
Rajala MW, Qi Y, Patel HR. 2004. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53, 1671–1679.
Savage DB, Sewter CP, Klenk ES. 2001. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes 50, 2199–2202.
Shuldiner AR, Yang R, Gong D-W. 2001. Resistin, obesity, and insulin resistance the emerging role of the adipocyte as an endocrine organ. N Engl J Med 345, 1345–6.
Steppan CM, Bailey ST, Bhat S. 2001. The hormone resistin links obesity to diabetes. Nature (London) 409, 307–312.
Tomaru T, Steger DJ, Lefterova MI, Schupp M, Lazar MA. 2009. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor γ and CCAAT/enhancerbinding proteins,” The Journal of Biological Chemistry 284(10), 6116–6125.
Ukkola O. 2002. Resistin, a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 147, 571-4.
Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S et al. 2005. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48(11), 2330-3.\
Zhang J, Qin Y, Zheng X. 2002. The relationship between human serum resistin level and body fat content, plasma glucose as well as blood pressure. Zhonghua Yi Xue Za Zhi 82, 1609–1612.
Eizadi Mojtaba, Khorshidi Davood, Seyedhoseini Mohammad Ali, Dooaly Hussein, 2011. Estimation of the correlation serum resistin with metabolic syndrome. Int. J. Biosci., 1(4), 118-124.
Copyright © 2011 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.